Royalty Pharma plc · NASDAQ:RPRX
Royalty Pharma — UBS Global Healthcare Conference (May 2021)
18 slides from Royalty Pharma's conference presentation, May 24, 2021
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: UBS Global Healthcare Conference
UBS Global Healthcare Conference Terrance Coyne, EVP, Chief Financial Officer Marshall Urist, EVP, Co-Head of Research & Investments May 24, 2021 2
Slide 3: Forward Looking Statements & Non-GAAP Financial Information
Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein do
Slide 4: Q1 2021 – Executing against our strategy
Q1 2021 – Executing against our strategy Strong double-digit top- and bottom-line growth(1) Robust deal flow with YTD transactions announced of $787m(2), including $582m upfront Exciting collaboration with MSCI on thematic indexes announced Raising full-year guidance for Adjusted Cash Receipts(3) (e
Slide 5: Royalty Pharma overview
Royalty Pharma overview Key Metrics Approved Products CF Franchise HIV Franchise Portfolio Metrics 45+ 21 ~15 Years Approved and Blockbuster Portfolio weighted development- $1bn+ therapies average royalty stage products in portfolio (1) duration Financial Metrics $1.8bn $1.5bn $1.7bn Adjusted Cash R
Slide 6: Diversified across products, TAs and blue-chip marketers
Diversified across products, TAs and blue-chip marketers 2020 Royalty Receipts By Product 2020 Royalty Receipts By Therapeutic Area 2020 Royalty Receipts By Marketer Other Other Other Cardiology Rare 14% 4% 15% 17% Hematology 4% Disease 6% 24% 24% 4% 3% 6% 6% Diabetes 4% 9% 5% (2) 6% 6% 15% Infectio
Slide 7: Strong Adjusted Cash Flow conversion in Q1 2021
Strong Adjusted Cash Flow conversion in Q1 2021 Q1 2021 Adjusted Cash Flow (Non-GAAP)(1) ($ in millions) 649 (126) 524 (42) (3) (63) $0.67/share(2) (7) 409 Royalty Receipts Non-Controlling Adjusted Cash Operating and R&D Funding Interest, net Other Adjusted Cash Flow Interest Receipts Professional C
Slide 8: 2020 was a record year for biopharma royalty funding
2020 was a record year for biopharma royalty funding Biopharma royalty market growth(1) Number of transactions Dollar value of transactions ($ in billions) 23 5.4 4.1 4.2 16 13 13 2.2 8 1.8 4 0.6 2015 2016 2017 2018 2019 2020 2015 2016 2017 2018 2019 2020 1. Internal estimates of historical biopharm
Slide 9: Royalty Pharma has maintained ~60% overall share since 2012
Royalty Pharma has maintained ~60% overall share since 2012 Estimated Royalty Market Size and Share by Transaction Value, 2012-May 2021(1) Royalty Pharma Other Royalty Buyers ~$2Bn ~$7Bn ~$6bn ~$13bn 18% 40% 66% 94% 82% 60% 34% 6% <$100m $100m - $250m $250m - $500m >$500m 1. Internal estimates of hi
Slide 10: Royalty Pharma has specific competitive advantages
Royalty Pharma has specific competitive advantages Other Buyers of Royalties Scale & Diversification Current portfolio of more than 45 products Comparable portfolios do not exist Publicly traded business with consistent cash flows Serial fund structures with Structure and the ability to leverage ent
Slide 11: Cabometyx - leading TKI approved in multiple indications
Cabometyx - leading TKI approved in multiple indications Sales evolution(1) ($ in millions) • Acquired GSK’s royalty in cabozantinib products Cabometyx/Cometriq +23% CAGR ▪ $342 million upfront, $50 million potential milestone payments 3,013(2) ▪ 3% royalty on worldwide net sales U.S. Non-U.S. • Cab
Slide 12: Oxlumo - transformative rare disease therapy for PH1
Oxlumo - transformative rare disease therapy for PH1 Primary Hyperoxaluria (PH) Type 1: • Acquired Dicerna’s royalty interest in Oxlumo (lumasiran) Patients in the U.S. / EU (2) ▪ $180 million upfront payment ▪ $60 million potential sales-based milestones ▪ Mid-high single digit royalty ~2,900-3,400
Slide 13: Our clear strategic plan to continue growth
Our clear strategic plan to continue growth Approved Late-Stage M&A therapies Development Select examples Select examples Select examples Acquire royalties on market- Acquire royalties on late-stage Acquire royalties through M&A leading approved therapies therapies with strong PoC data transactions
Slide 14: Agnostic to therapeutic areas, modalities and drug class
Agnostic to therapeutic areas, modalities and drug class Portfolio Agnostic to Therapeutic Areas and Unique Ability to Invest in Multiple Core Treatment Modalities Products in the Same Class Anti-TNFs Rare Disease Immunology (AbbVie) (Johnson & Johnson) (UCB) HIV Migraine 45+ (Eli Lilly) (Biohaven)
Slide 15: Acquire approved and de-risked development-stage royalties
Acquire approved and de-risked development-stage royalties Approved Status at Acquisition(1) Current Status(1) Since Acquisition Approved Products(2) • Predictable and de-risked Development-Stage Products Not Approved cash flows Total - $15.8bn $0.4bn, 2% $0.4bn, 3% (3) • Growth from increased penet
Slide 16: Significant untapped opportunity for synthetic royalties
Significant untapped opportunity for synthetic royalties Capital Raised by Biotech Companies, 2015-2019(1) • A synthetic royalty is created by the developer and/or marketer >$170bn of a therapy in exchange for funding • Multiple benefits to biotech partner: • Non-dilutive program-specific funding at
Slide 17: A unique business at the center of biopharma innovation
A unique business at the center of biopharma innovation Well positioned to leverage fast pace of biopharma innovation Agnostic to therapeutic categories and modalities Direct exposure to growth of transformative blockbuster therapies Long duration portfolio, highly diversified across products, thera
Slide 18: Footnotes
Footnotes 1) To aid in comparability, figures for each fiscal quarter in 2019 are presented on an unaudited pro forma basis, which adjusts certain cash flow line items as if Royalty Pharma’s Reorganization Transactions (as described in the Company’s final prospectus filed with the SEC on June 17, 20
Royalty Pharma — UBS Global Healthcare Conference (May 2021) on 6ix